Fortrea Holdings (FTRE) Depreciation & Amortization (CF) (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Depreciation & Amortization (CF) came in at $19.6 million in Q2 2026, little changed YoY from $19.6 million in Q2 2025, and down 1.01% on a QoQ basis from $19.8 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Depreciation & Amortization (CF) data on file, last reported at $19.6 million in Q2 2026.
- Quarterly Depreciation & Amortization (CF) changed 0.0% year-over-year to $19.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $78.3 million (down 3.45% YoY) and the FY2025 annual result came in at $78.0 million, down 10.24% from the prior year.
- Depreciation & Amortization (CF) eased to $19.6 million in Q2 2026, from $19.8 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $25.1 million in Q2 2023 to a low of $19.3 million in Q4 2025.
- A 5-year average of $21.9 million and a median of $21.4 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) grew 8.37% — and 2025, when it declined 17.02%.
- Tracing FTRE's Depreciation & Amortization (CF) over 5 years: stood at $23.9 million in 2022, then increased by 2.09% to $24.4 million in 2023, then slipped by 14.75% to $20.8 million in 2024, then slipped by 7.21% to $19.3 million in 2025, then rose by 1.55% to $19.6 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $19.6 million (Q2 2026), $19.8 million (Q1 2026), and $19.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | Fortrea Holdings | 1.73 Bn | 1.56 Bn | 139.20 Mn | 19.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.60 Mn |
| Mar 31, 2026 | 19.80 Mn |
| Dec 31, 2025 | 19.30 Mn |
| Sep 30, 2025 | 19.60 Mn |
| Jun 30, 2025 | 19.60 Mn |
| Mar 31, 2025 | 19.50 Mn |
| Dec 31, 2024 | 20.80 Mn |
| Sep 30, 2024 | 21.20 Mn |
| Jun 30, 2024 | 21.40 Mn |
| Mar 31, 2024 | 23.50 Mn |
| Dec 31, 2023 | 24.40 Mn |
| Sep 30, 2023 | 24.60 Mn |
| Jun 30, 2023 | 25.10 Mn |
| Mar 31, 2023 | 23.10 Mn |
| Dec 31, 2022 | 23.90 Mn |
| Sep 30, 2022 | 22.70 Mn |
| Jun 30, 2022 | 23.40 Mn |